Kurzrock, Razelle

PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,291

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,264

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,192

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 573

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 552

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology

Thyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatment

Cited by 550

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 507

Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study

Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 506

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine

RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions

Cited by 445

Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics

Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer

Cytokine Signaling Pathways and InteractionsRheumatoid Arthritis Research and Therapies

Cited by 370

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics

Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology

Cancer Genomics and DiagnosticsCancer Mechanisms and Therapy

Cited by 328

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research

Genomics, phytochemicals, and oxidative stressBioactive Compounds and Antitumor Agents

Cited by 236

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

Naing, A., LoRusso, P., Fu, S., Hong, D. S., Anderson, P., Benjamin, R. S., Ludwig, J., Chen, H. X., Doyle, L. A., & Kurzrock, R. (2012) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 205

Targeting ARID1A mutations in cancer

Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews

Chromatin Remodeling and CancerOvarian cancer diagnosis and treatment

Cited by 186

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma

Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 164

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and Mutations

Cited by 115

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients

Schwaederle, M., Daniels, G. A., Piccioni, D. E., Fanta, P. T., Schwab, R. B., Shimabukuro, K. A., Parker, B. A., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 90

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J. (2017) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 70

Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid

Estey, E., Thall, P., Mehta, K., Rosenblum, M., Brewer, T. J., Simmons, V, Cabanillas, F., Kurzrock, R., & Lopez-Berestein, G. (1996) · Blood

Retinoids in leukemia and cellular processesPeroxisome Proliferator-Activated Receptors

Cited by 66

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival

Kato, S., Schwaederlé, M. C., Fanta, P. T., Okamura, R., Leichman, L., Lippman, S. M., Lanman, R. B., Raymond, V. M., Talasaz, A., & Kurzrock, R. (2019) · JCO Precision Oncology

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Cited by 52

Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

Kurzrock, R., Goel, S., Wheler, J., Hong, D., Fu, S., Rezai, K., Morgan‐Linnell, S. K., Urien, S., Mani, S., Chaudhary, I., et al. (2012) · Cancer

Cancer therapeutics and mechanismsPharmacogenetics and Drug Metabolism

Cited by 50

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

Tibes, R., Falchook, G. S., Von Hoff, D. D., Weiss, G. J., Iyengar, T., Kurzrock, R., Pestano, L., Lowe, A. M., & Herbst, R. S. (2010) · Journal of Clinical Oncology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 46

Farnesyltransferase inhibitors: where are we now?

Tsimberidou, A. M., Chandhasin, C., & Kurzrock, R. (2010) · Expert Opinion on Investigational Drugs

Acute Myeloid Leukemia ResearchProtein Tyrosine Phosphatases

Cited by 39

Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 34